A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Collagen alpha-2(IX) chain is a protein that in humans is encoded by the COL9A2 gene. This gene encodes one of the three alpha chains of type IX collagen, the major collagen component of hyaline cartilage. Type IX collagen, a heterotrimeric molecule, is usually found in tissues containing type II collagen, a fibrillar collagen. This chain is unusual in that, unlike the other two type IX alpha chains, it contains a covalently attached glycosaminoglycan side chain. Mutations in this gene are associated with multiple epiphyseal dysplasia.
== Exceptions == Genetics does not determine the language spoken by a human being, and the link between Y-chromosomal haplogroups and linguistic affinities is an observed correlation and not a causal link. While father tongues predominate, exceptions to father tongues exist in the world. One possible exception is the Balti in northern Pakistan. The mtDNA haplogroups most frequent among Balti are the same as those of the neighbouring Tibetan communities, whereas the Y-chromosomal haplogroups most frequent in Balti males appear to have entered Baltistan from the west with the introduction of Islam. The Balti speak one of the most conservative Tibetan languages. The language of the Balti corresponds to the mtDNA and not to the Y chromosome and is in effect a salient example of a mother tongue.
== Diagnosis == Screening for muscle atrophy is limited by a lack of established diagnostic criteria, although many have been proposed. Diagnostic criteria for other conditions such as sarcopenia or cachexia can be used. These syndromes can also be identified with screening questionnaires. Muscle mass and changes can be quantified on imaging studies such as CT scans or Magnetic resonance imaging (MRI). Biomarkers such as urine urea can be used to roughly estimate muscle loss during circumstances of rapid muscle loss. Other biomarkers are currently under investigation but are not used in clinical practice.
==== 2400–2499 ==== County Council of Clwyd (River Dee Estuary Bridge) Scheme 1992 Confirmation Instrument 1993 (S.I. 1993/2400) Environmental Protection (Prescribed Processes and Substances) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2405) Offshore Safety Act 1992 (Commencement No. 1) Order 1993 (S.I. 1993/2406) Leasehold Reform (Collective Enfranchisement and Lease Renewal) Regulations 1993 (S.I. 1993/2407) Rent Assessment Committee (England and Wales) (Leasehold Valuation Tribunal) Regulations 1993 (S.I. 1993/2408) Leasehold Reform (Notices) (Amendment) Regulations 1993 (S.I. 1993/2409) Local Government and Housing Act 1989 (Commencement No. 16) Order 1993 (S.I. 1993/2410) National Health Service (General Medical Services) Amendment (No. 2) Regulations 1993 (S.I. 1993/2421) Environmentally Sensitive Areas (Ynys Mo*n) Designation (Amendment) Order 1993 (S.I. 1993/2422) Patents (Amendment) Rules 1993 (S.I. 1993/2423) Pembrokeshire National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2436) Strathclyde Region (Electoral Arrangements) Order 1993 (S.I. 1993/2439) Finance Act 1993, Section 18, (Appointed Day) Order 1993 (S.I. 1993/2446) National Health Service (General Medical and Pharmaceutical Services) (Scotland) Amendment (No. 2) Regulations 1993 (S.I. 1993/2449) Social Fund Cold Weather Payments (General) Amendment Regulations 1993 (S.I. 1993/2450) National Health Service (Pharmaceutical Services) Amendment Regulations 1993 (S.I. 1993/2451) Vehicles Excise Duty (Simplification of Goods Vehicles Rates) Order 1993 (S.I.
Sources: en.wikipedia.org
== Adverse effects == Side effects of mescaline include fatigue, weakness, impaired concentration, restlessness, tension, anxiety, panic, and social discomfort and avoidance, headache, pupil dilation, nausea, vomiting, sweating, trembling, discomfort, feeling hot or cold, palpitations, chest and neck pains, shortness of breath, increased heart rate and blood pressure, and increased body temperature, among others. Nausea and vomiting are important dose-limiting side effects of mescaline and occur at greater rates than with other psychedelics like LSD and psilocybin. High doses of mescaline, such as 800 mg and above, are not well-tolerated due to substantial nausea and vomiting. On the other hand, mescaline appears to induce less fear and anxiety than LSD and psilocybin even at equivalent doses.
=== New Zealand === PCP was used in New Zealand as a timber preservative and antisapstain treatment, but since 1988 is no longer used. It was also sold as a moss killer to the general public (by Shell, at least) in the form of a 115g/L aqueous solution and labelled as a poison.
==== Physical performance ==== Caffeine is a proven ergogenic aid in humans. Caffeine improves athletic performance in aerobic (especially endurance sports) and anaerobic conditions. Moderate doses of caffeine (around 5 mg/kg) can improve sprint performance, cycling and running time trial performance, endurance (i.e., it delays the onset of muscle fatigue and central fatigue), and cycling power output. Caffeine increases basal metabolic rate in adults. Caffeine ingestion prior to aerobic exercise increases fat oxidation, particularly in persons with low physical fitness. Caffeine improves muscular strength and power, and may enhance muscular endurance. Caffeine also enhances performance on anaerobic tests. Caffeine consumption before constant load exercise is associated with reduced perceived exertion. While this effect is not present during exercise-to-exhaustion exercise, performance is significantly enhanced. This is congruent with caffeine reducing perceived exertion, because exercise-to-exhaustion should end at the same point of fatigue. Caffeine also improves power output and reduces time to completion in aerobic time trials, an effect positively (but not exclusively) associated with longer duration exercise.
Sources: en.wikipedia.org
The ineffectual response was caused by feuding officials who refused to co-operate with each other contributed to the death toll. It took weeks for aid to reach some villages, causing much resentment in Calabria. To offset widespread criticism that the government in Rome did not care about Calabria, King Victor Emmanuel III personally took over the relief operation and toured the destroyed villages of Calabria, which won the government a measure of popularity. Notably, after the king took charge, the feuding ceased and aid started to flow.
=== Type 2 diabetes === Liraglutide improves control of blood glucose. In people with high cardiovascular risk, liraglutide has been shown to reduce the risk for first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. American Diabetes Association (ADA) guidelines consider liraglutide a first line pharmacologic therapy for type 2 diabetes (usually together with metformin), specifically for people with atherosclerotic cardiovascular disease or obesity. A 2011 Cochrane review showed a HbA1c reduction of 0.24% more with liraglutide 1.8 mg compared to insulin glargine, 0.33% more than exenatide 10 μg twice daily, sitagliptin and rosiglitazone. In a randomized controlled trial (RCT) comparing liraglutide, glargine, glimepiride, and sitagliptin (all added to metformin) with a follow-up of five years, glargine and liraglutide were modestly more effective in achieving and maintaining target HbA1c, with no difference in outcomes of microvascular and cardiovascular disease.
=== Category:EC 1.17 (act on CH or CH2 groups) === Category:EC 1.17.1 Leucoanthocyanidin reductase EC 1.17.1.3 Xanthine dehydrogenase EC 1.17.1.4 Nicotinate dehydrogenase EC 1.17.1.5 4-hydroxy-tetrahydrodipicolinate reductase EC 1.17.1.8 Category:EC 1.17.2 Nicotinate dehydrogenase (cytochrome) EC 1.17.2.1 Category:EC 1.17.3 Xanthine oxidase EC 1.17.3.2 Category:EC 1.17.4 Ribonucleotide reductase EC 1.17.4.1 Ribonucleoside-triphosphate reductase EC 1.17.4.2 Vitamin K epoxide reductase Vitamin-K-epoxide reductase (warfarin-sensitive) EC 1.17.4.4 Vitamin-K-epoxide reductase (warfarin-insensitive) EC 1.17.4.5 RRM1 RRM2 RRM2B Category:EC 1.17.5 Caffeine dehydrogenase EC 1.17.5.2 Category:EC 1.17.7 Category:EC 1.17.99
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.